Stock Financial Ratios

KPTI / Karyopharm Therapeutics Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)503.23
Enterprise Value ($M)356.62
Book Value ($M)162.24
Book Value / Share3.87
Price / Book4.88
NCAV ($M)113.49
NCAV / Share4.37
Price / NCAV7.07
Income Statement (mra) ($M)
Net Income-109.58
Balance Sheet (mrq) ($M)
Cash & Equivalents54.45
Cash / Share1.45
Quick Ratio7.99
Current Ratio7.99
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.68
Return on Assets (ROA)-0.61
Return on Equity (ROE)-0.68
Identifiers and Descriptors
Central Index Key (CIK)1503802
Industry Groups
SIC 2834 - Pharmaceutical Preparations
Other Related CUSIPS
Share Statistics
Common Stock Shares Outstanding41,887,829
Common Shares Outstanding41,901,205
Preferred Stock Shares Outstanding0
Scoring Models
Piotroski F-Score1.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Per Share Metrics
Intangibles Per Share0.00
Liabilities Per Share0.60
Accumulated Depreciation And Depletion Per Share0.00
Equity Per Share0.00
Minority Interest Per Share0.00
Property Plant And Equipment Gross Per Share0.00
Accounts Receivable Per Share0.00
Property Plant And Equipment Per Share0.00
Inventory Raw Materials Per Share0.00
Long Term Debt Per Share0.00
Treasury Stock Per Share0.00
Accounts Payable Per Share0.00
Assets Per Share3.91
Assets Non Current Per Share0.00
Inventory Per Share0.00
Retained Earnings Per Share0.00
Cash And Equivalents Per Share1.30
Liabilities And Stock Equity Per Share0.00
Assets Other Non Current Per Share0.00
Inventory Work In Progress Per Share0.00
Goodwill Per Share0.00
Property Plant And Equipment Net Per Share0.00
Additional Paid In Capital Per Share0.00
Liabilities Current Per Share0.00
Assets Current Per Share2.90
Debt Per Share0.00
Deferred Income Tax Liabilities Per Share0.00
Current Portion Of Long Term Debt Per Share0.00
Cash Per Share1.45
Assets Other Current Per Share0.00
Inventory Finished Goods Per Share0.00
Liabilities Other Non Current Per Share0.00
Preferred Stock Value Outstanding Per Share0.00

Peers - Pharmaceutical Preparations (2834)

Related News Stories

Biotech Forum Daily Digest For February 15th

2018-02-15 seekingalpha
The biotech sector has stabilized and rallied this week like the rest of the overall market after two weeks of deep declines. (71-1)

Biogen's Deal Is A Partial Step In The Right Direction, But A Bigger Acquisition Is In Order

2018-01-29 seekingalpha
Biogen made a small deal, but should look to acquire a bigger biotech company for further growth. (93-2)

U.S. Biotech/Pharma Sector Daily Observations Letter: Jan. 25, 2018

2018-01-26 seekingalpha
Consolidation ongoing in S&P 500 index (SPY) for two days but another high likely. High yield bonds (HYG) are going down but at a support. VIX continued to creep up today. (269-0)

Biogen Earnings: Spinraza Faces A Rough Ride - Bloomberg

2018-01-25 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (19-0)

Your Daily Pharma Scoop: Synergy's Trulance Gets Approval In IBS-C, Biogen Announces Q4 Results, Summit's Positive Interim Results

2018-01-25 seekingalpha
Today we will discuss Synergy Pharmaceuticals (SGYP), which as expected has been granted an approval for Trulance 3 mg tablet as a once-daily treatment of irritable bowel syndrome with constipation (IBS-C) in adults. This is the second indication in which Trulance has approved. The FDA has last year approved the drug as a treatment for chronic idiopathic constipation (CIC) in adults. (454-4)

CUSIP: 48576U106